Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands.
about
The Ashwell receptor mitigates the lethal coagulopathy of sepsisSialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation.Initiation of protein O glycosylation by the polypeptide GalNAcT-1 in vascular biology and humoral immunity.The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contentsRole of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes.Novel clearance mechanisms of platelets.A novel type of macrothrombocytopenia associated with a defect in α2,3-sialylation.Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.Reduced human platelet uptake by pig livers deficient in the asialoglycoprotein receptor 1 protein.Altered eosinophil profile in mice with ST6Gal-1 deficiency: an additional role for ST6Gal-1 generated by the P1 promoter in regulating allergic inflammation.A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in miceMilk sialyllactose influences colitis in mice through selective intestinal bacterial colonization.Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists.ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signalingSystemic blockade of sialylation in mice with a global inhibitor of sialyltransferases.The role of lectins and glycans in platelet clearanceNovel and unexpected clearance mechanisms for cold plateletsST3Gal-4 is the primary sialyltransferase regulating the synthesis of E-, P-, and L-selectin ligands on human myeloid leukocytes.Reduced sialylation impacts ventricular repolarization by modulating specific K+ channel isoforms distinctly.The genetics of common variation affecting platelet development, function and pharmaceutical targeting.Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest: short communicationDual roles for hepatic lectin receptors in the clearance of chilled plateletsBirth Cohort, Age, and Sex Strongly Modulate Effects of Lipid Risk Alleles Identified in Genome-Wide Association Studies.Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice.Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation.Expression of functional P-selectin glycoprotein ligand 1 on hematopoietic progenitors is developmentally regulated.ABO Blood Group as a Model for Platelet Glycan Modification in Arterial ThrombosisNEU1 and NEU3 sialidase activity expressed in human lung microvascular endothelia: NEU1 restrains endothelial cell migration, whereas NEU3 does notThe origin and function of platelet glycosyltransferases.Association of Single Nucleotide Polymorphisms in the ST3GAL4 Gene with VWF Antigen and Factor VIII Activity.Coordinated roles of ST3Gal-VI and ST3Gal-IV sialyltransferases in the synthesis of selectin ligands.ASGR1 and ASGR2, the Genes that Encode the Asialoglycoprotein Receptor (Ashwell Receptor), Are Expressed in Peripheral Blood Monocytes and Show Interindividual Differences in Transcript ProfileBiosynthesis of the major brain gangliosides GD1a and GT1bHuman Plasma N-glycosylation as Analyzed by Matrix-Assisted Laser Desorption/Ionization-Fourier Transform Ion Cyclotron Resonance-MS Associates with Markers of Inflammation and Metabolic Health.An intrinsic mechanism of secreted protein aging and turnoverABO blood group determines plasma von Willebrand factor levels: a biologic function after all?Clearance mechanisms of von Willebrand factor and factor VIII.Control of post-translational modifications in antithrombin during murine post-natal development by miR-200aRelationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications.
P2860
Q24596452-14EF4090-E375-4884-9044-94C10142211FQ30440648-C9C9EE4E-42F3-408A-BEC1-99E4ABB594B7Q30443305-0E851D90-4987-4C80-9A78-5935B1232B9EQ33364277-DDABFF03-8D60-4CD9-A41A-C7B86C64A829Q33384971-5FD97976-FF50-498A-B2EF-F514A79F71E7Q33391541-5EC07266-0119-4C89-A801-C50565142C38Q33396841-A3B67198-DDC3-4455-814D-A5A31F261944Q33411767-5795061A-6F07-4E1C-8E32-F95AEF0BE10EQ33420790-50C2BDC9-7A4A-4F2D-895F-85B4C1F2EE41Q33694538-81E9D5CC-4513-45F1-90E8-5656627AB19EQ33917215-47E3454A-6B0C-4A11-9FE7-33B385B659A8Q34420808-2EE53E35-1A3C-428C-BCD3-BA396F99DC78Q34674600-1BFBD33F-C246-4F9D-812C-AD350A92234AQ34718297-AD970BB8-AB4C-426C-8297-233466F71C18Q34737768-B0F1BA2F-D928-4C86-99E3-3506D4BF8311Q35000830-CB554B0A-8418-48FF-96CB-284F0917D688Q35000878-003E301C-5153-4893-A003-1E438DB538E9Q35004977-90B72CB2-7B75-442E-8306-7BD0E00A246FQ35048797-BF598429-F85A-416F-BFDA-4A969AEBADFDQ35149898-74A6BFC7-5E40-4A9D-AC4C-104EE2C03C5FQ35159004-ECADDECD-FF9D-4039-B009-21F98E88B54BQ35595835-87C8CBD9-3F3C-44F3-8C74-533354651A69Q35752147-07644EE4-E329-4278-B274-3298FC4909CDQ35754002-3B19F2FB-5A33-46CE-8679-96715B1D53C9Q35848737-1E74BFB3-6339-4208-B585-A75CA5290614Q35856788-E2D53FC7-19C8-4AC5-A362-0081E79B15A0Q35903416-5DAE9489-238E-4FE3-BCF5-9FCD61576A1FQ35907051-A9F7E4CA-29D3-45A6-B4E3-DD64725B3409Q35939859-5B3AC9A5-85BE-4D02-86EC-CD74BAC8F95AQ36106312-A88C39CC-36E1-44D4-A381-1AA6A5D7937CQ36120096-7B2AEB1D-22D3-4511-A347-CF0E863B0666Q36141826-3651F448-19E3-45F2-BE58-7BFFDE3C32DDQ36165181-59E0C7AE-DBC8-4F4A-A1E8-66CB418CA1F5Q36182168-8437A300-7731-48AC-8C97-E5CF5AA413BCQ36216763-54CF7212-44DC-404C-9934-653D0B61C0CBQ36268471-A1BCDA99-F399-4DF7-9511-932DFA59FCDDQ36604393-C6F1184B-E9F3-444A-B899-06FC892C653FQ36787433-D26168DA-D4F4-440C-B449-F8CD5603F77FQ36908636-9FC7253E-5FB0-409F-9CE3-4BA338BC163FQ36951311-2A7EF4CC-B339-4BEB-AD4A-4D11783CD278
P2860
Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Sialyltransferase ST3Gal-IV op ...... glycoprotein receptor ligands.
@ast
Sialyltransferase ST3Gal-IV op ...... glycoprotein receptor ligands.
@en
type
label
Sialyltransferase ST3Gal-IV op ...... glycoprotein receptor ligands.
@ast
Sialyltransferase ST3Gal-IV op ...... glycoprotein receptor ligands.
@en
prefLabel
Sialyltransferase ST3Gal-IV op ...... glycoprotein receptor ligands.
@ast
Sialyltransferase ST3Gal-IV op ...... glycoprotein receptor ligands.
@en
P2093
P2860
P356
P1476
Sialyltransferase ST3Gal-IV op ...... glycoprotein receptor ligands.
@en
P2093
Ajit Varki
David Ditto
David Ginsburg
Dzung T Le
Gallia G Levy
Jamey D Marth
Lesley G Ellies
Mark Wahrenbrock
P2860
P304
10042-10047
P356
10.1073/PNAS.142005099
P407
P577
2002-07-03T00:00:00Z